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We have investigated whether immunohistochemical markers can identify differences in cell cycle phase distribution in ovarian serous
neoplasms, including borderline tumours of different grades. Sections of normal ovary (n¼18), serous cystadenoma (n¼21),
borderline serous tumours (n¼21) and serous cystadenocarcinoma (n¼15) were analysed by immunohistochemistry using markers
of cell cycle entry (Mcm-2) and cell cycle phase, including cyclin D1 (mid-to-late G1), cyclin A (S phase), cyclin B1 (G2 phase) and
phosphohistone H3 (mitosis). Double-labelling confocal microscopy confirmed marker phase specificity and phase estimations were
corroborated by flow cytometry. On progression from normal ovary through serous cystadenoma and borderline tumours to
cystadenocarcinomas, expression of Mcm-2 (Po0.0001), cyclin D1 (P¼0.002), cyclin A (Po0.0001), cyclin B1 (Po0.0001) and
phosphohistone H3 (Po0.0001) increased, paralleled by an increase in the S-phase fraction (cyclin A:Mcm-2 ratio; P¼0.002).
Borderline tumours of increasing grade also showed increased Mcm-2 and cyclin A expression, together with an increase in the S-
phase fraction. Immunohistochemistry can be used to estimate cell cycle phase distribution in ovarian serous neoplasms, giving results
similar to flow cytometric analysis and enabling direct assessment of tumour heterogeneity. Immunohistochemical estimates of the S-
phase fraction may identify serous borderline tumours likely to exhibit malignant progression and/or select serous
cystadenocarcinomas likely to respond to adjuvant therapy.
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Neoplasms of the ovarian surface epithelium account for 60% of all
ovarian tumours. They are divided into serous, mucinous,
endometrioid and other types, of which serous are the most
common (Fox and Buckley, 1992; Zaloudek, 2000). Serous tumours
are classified further into benign, borderline and malignant
neoplasms. The borderline group is of special interest because,
although the majority of these tumours will behave in a benign
manner, 15–30% will progress to an invasive malignancy and such
tumours have a poor prognosis. The ability to differentiate reliably
between those borderline tumours that will behave in a benign
manner and those with a propensity to progress is essential, as
tumours described as borderline on histological examination are
treated differently from those displaying a malignant phenotype
(Russell, 1994; Dietel and Hauptmann, 2000). Indeed, in the
younger patient, the diagnosis of a borderline tumour may result
in conservative treatment, and failure to remove the contralateral
ovary. As recurrences in borderline tumours are often bilateral,
conservative treatment and the failure to remove both ovaries at
initial surgery often results in aggressive disease with a very poor
prognosis (Russell, 1994). At the present time, there is no reliable
method of histological differentiation between those borderline
tumours destined for malignant progression and those that are
likely to behave in a benign manner. Consequently, some tumours
that will progress to a malignant phenotype will be missed despite
careful histological examination (Dietel and Hauptmann, 2000).
It has been suggested that ovarian tumours having a high S-
phase fraction behave in a more aggressive manner (Skirnisdottir
et al, 2001) and that, conversely, tumours with a low proliferation
index respond poorly to chemotherapy (Itamochi et al, 2002). We
have developed a strategy, based on immunohistochemistry, to
allow cell cycle phase analysis to be performed on paraffin-
embedded tissue in the routine diagnostic laboratory (Scott et al,
2003). Such an approach will be applicable in any histopathology
laboratory capable of performing immunohistochemistry, unlike
the complex techniques of flow cytometry and cytogenetics, which
are difficult to apply in the diagnostic setting. We ultimately aim to
determine whether or not cell cycle phase parameters, as
determined by immunohistochemistry, are of prognostic signifi-
cance in ovarian tumour pathology, either in the prediction of
outcome/rate of progression of ovarian serous cystadenocarcino-
mas or in the differentiation between low- and high-risk borderline
serous tumours.
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MCM proteins (MCM 2–7) that assemble in the prereplication
complex and are essential for DNA replication in eukaryotic cells
(Tye, 1999; Lei and Tye, 2001). All six proteins are abundant
throughout the cell cycle and are broken down rapidly on
differentiation or more slowly in quiescence (Musahl et al, 1998;
Todorov et al, 1998). Antibodies against MCMs such as Mcm-2 or
Mcm-5 have been shown to be of value in identifying malignant or
premalignant lesions in a range of specimens (Williams et al, 1998;
Freeman et al, 1999; Meng et al, 2001; Wharton et al, 2001; Davies
et al, 2002; Going et al, 2002; Hunt et al, 2002). We have also
demonstrated the potential for antibodies raised against cyclins
D1, A, B1 and phosphorylated histone H3 to estimate cell cycle
phase distribution by immunohistochemistry (Scott et al, 2003).
Cyclin D1 is maximally expressed in mid-to-late G1 and is involved
in the G1/S transition (Coverley et al, 2002). Cyclin A is generally
maximally expressed in S phase, with only low-level expression in
G2 (Pines and Hunter, 1992; Hunter and Pines, 1994; Yam et al,
2002; Scott et al, 2003). The exact pattern of expression appears,
however, to vary according to the nature and type of cell line used,
with some cell lines showing low-level cyclin A expression into
early metaphase (Yam et al, 2002). Cyclin B1 is expressed as a
cytoplasmic molecule in G2 but becomes located within the
nucleus in early mitosis (M) until the breakdown of the nuclear
membrane, at which point staining becomes diffuse (Pines and
Hunter, 1992; Nasmyth, 1996). Phosphohistone H3 is specific for
mitosis and is rapidly degraded on entry into G1 (Shibata and
Ajiro, 1993). Antibodies against this set of markers might enable,
therefore, in situ labelling of cells at all phases of the cell cycle, with
the exception of early G1, for which no useful marker is currently
available.
As this method of analysing cell cycle kinetics in the ovary is
novel, we compared our findings with those obtained using the
established method of flow cytometry. The relative phase
specificity of each marker was also established in the ovary by
double labelling and confocal microscopy to ensure that there was
no significant coexpression of putative markers of adjacent cell
cycle phases. Such data would be consistent with our observations
in tumours at other anatomical sites (Scott et al, 2003). The ability
to estimate the S-phase fraction in paraffin-embedded ovarian
tumour tissue would allow this parameter to be included in
existing diagnostic algorithms and may allow the identification of
tumours that respond well to adjuvant therapy. The method would
also enable retrospective studies to be performed on archival
material, thus avoiding the need for lengthy prospective studies
and the requirement for frozen material for reliable flow
cytometric analysis.
MATERIALS AND METHODS
Resection specimens
Archival blocks of anonymised formalin-fixed, paraffin-embedded
specimens of human ovary were obtained in accordance with Local
Research Ethics Committee guidelines. The tissues examined
represented normal ovary (n¼18), serous cystadenomas
(n¼21), borderline serous neoplasms (n¼21) and serous
cystadenocarcinomas (n¼15).
Immunohistochemical staining of paraffin-embedded
sections
Sections (5mm) were cut onto aminopropyltriethoxysilane (APES)-
coated slides and were processed for immunohistochemistry as
described previously (Freeman et al, 1999). Mouse monoclonal
antibodies raised against the following antigens were used:
minichromosome maintenance protein-2 (Mcm-2) (Davies et al,
2002); Cyclin D1 (Nova Castra, Newcastle, UK); Cyclin A (Nova
Castra, Newcastle, UK); and Cyclin B1 (DAKO, Ely, UK). We also
used rabbit polyclonal antibodies raised against Mcm-5 (Williams
et al, 1998) to facilitate double labelling, and a rabbit polyclonal
against phosphohistone H3 (Upstate Biotechnology, Lake Placid,
NY, USA). Antigen retrieval was achieved by pressure cooking for
3min in citrate buffer (pH 6.0), except for the cyclin D1
preparations for which antigen retrieval was achieved by heating
in a programmable microwave oven (MicroMED T/T Mega,
Sorisole, Italy) for 30min at 981C. We found that the staining
pattern obtained with cyclin D1 was highly dependent upon the
conditions used to facilitate antigen retrieval. A high pH buffer
(DAKO high pH antigen retrieval solution (pH 9.6), DAKO, Ely,
UK) and heating in a microwave oven produced predominantly
nuclear staining, whereas neutral or low pH buffers, particularly
when combined with pressure cooking, gave a mixed cytoplasmic/
nuclear pattern. In addition, minimal background staining was
achieved when cyclin D1 primary antibodies were detected using
the EnVision system (DAKO, Ely, UK). Negative controls were
performed by omitting the primary antibody. Sections of cervix
showing various grades of intraepithelial neoplasia were used as
positive controls.
Double labelling studies
In order to test the validity of using antibodies to estimate cell
cycle phase in situ, double labelling experiments were performed
in ovarian serous borderline tumours and serous cystadenocarci-
nomas (n¼6 in each group) as previously described (Scott et al,
2003). In the first series of reactions, Mcm-2 or Mcm-5 was
combined with each of the four putative phase markers, cyclin D1,
cyclin A, cyclin B1 and phosphohistone H3. We tested the
hypothesis that if antibodies against MCMs identify all cells in
cycle, none of the cyclins or phosphohistone H3 antibodies should
detect cells negative for Mcm-2/5. The second series of reactions
was designed to investigate the frequency of coexpression of the
different markers of cell cycle phase. Markers were paired as
follows: phosphohistone H3-cyclin D1 (putative markers of M and
G1 phases); cyclin D1-cyclin A (G1 and S phases); cyclin A-cyclin
B1 (S and G2 phases); and cyclin B1-phosphohistone H3 (G2 and
M phases).
Where the primary antibodies had been raised in different
species they were added together and incubated overnight.
Following washing, both secondary antibodies (Alexa Fluro goat
anti-mouse 488 and Alexa Fluro goat anti-rabbit 546; Molecular
Probes) were added together and incubated for one hour. After
further washing, slides were counterstained using 4,6-diamidino-2-
phenylindole (DAPI) (Sigma, Poole, Dorset, UK), washed and
mounted in fluorescent mounting medium (DAKO, Ely, UK).
When the primary antibodies were both mouse monoclonals a
different procedure was performed. Initially, one of the primary
antibodies was applied alone. After washing, the sections were
incubated with Alexa Fluro goat anti-mouse 488 (Molecular
Probes) and this was followed by a blocking step with F(ab)2 goat
anti-mouse IgG fragments (Jackson Immuno Research Labora-
tories). A further washing step was then performed before
incubation with the second primary antibody. Following a final
washing step and incubation in Alexa Fluro goat anti-mouse 633
(Molecular Probes), the slides were counterstained and mounted as
described above.
Images were viewed and assessed using a Zeiss Axioplan 2
confocal microscope at wavelengths of 488, 546 and 633nm.
Flow cytometry
A subset of serous cystadenocarcinomas (n¼10) was selected for
additional flow cytometric analysis, to allow comparison between
the cell cycle phase distributions determined by flow cytometry
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yand those estimated by immunohistochemistry. The cases were
selected on the basis that the biopsy was composed almost entirely
of tumour and contained a minimal inflammatory cell infiltrate,
thus minimising contamination of the preparation by non-
neoplastic cell nuclei.
Sections (50mm) were cut from paraffin blocks into Eppendorf
tubes. The sections were dewaxed in xylene and taken through
decreasing concentrations of alcohol until final equilibration was
achieved in phosphate-buffered saline (pH 7.4). The samples were
then incubated for 1h at 371C in the presence of 1mg/ml
collagenase and 1mg/ml trypsin. The sample was then passed
through a 23-G needle to disperse clumps and the nuclei were
precipitated by centrifugation at 300g for 5min. RNA was
removed by incubation in RNase A (100mgml
 1) for 30min at
371C. The nuclei were then repelleted at 300g for 5min, washed in
PBS and passed through a 70mm sieve. The nuclei were stained
using propidium iodide (50mgml
 1) and were assessed using an
argon laser tuned to 488nm. The fraction of cells in each phase of
the cycle was analysed using CELLQuest Software (Becton
Dickinson, Cowley, UK).
Quantitation of immunohistochemical staining
For sections of normal ovary and serous cystadenomas, the lining
of serous inclusions and strips of cyst wall, respectively, were
examined. The number of cells expressing each putative phase
marker was determined both as a percentage of the total number of
cells (termed a labelling index, LI) and as a percentage of the
number of Mcm-2 positive epithelial cells (termed a labelling
fraction, LF). LFs were determined to indicate the proportions of
the cells in cycle that were in each cycle phase. For the borderline
serous tumours and the serous cystadenocarcinomas, similar
counts were performed, although for these tumours the percentage
of the total number of cells expressing each antigen was established
for three random high magnification microscopic fields rather
than for epithelial strips. Approximately 1000 cells were counted
for each case by three individual observers and the interobserver
variation was less than 5%.
Cell cycle analyses obtained by immunohistochemistry were
compared directly with those obtained by flow cytometry for 10
cases of serous cystadenocarcinoma. In the immunohistochemical
analysis, estimates of the percentage of total epithelial cells in S, G2
and M were derived from the cyclin A LI, the cyclin B1 LI and the
phosphohistone H3 LI, respectively. An estimate of the percentage
of cells in G1 was derived by subtracting the combined LIs of
cyclin A, cyclin B1 and phosphohistone H3 from the Mcm-2 LI. An
estimate of the percentage of epithelial cells in G0 was derived
from the percentage of total epithelial cells that were Mcm-2
negative.
Analysis of borderline serous neoplasms
We investigated whether cell cycle parameters varied within the
group of 21 borderline serous neoplasms. Information regarding
tumour recurrence and outcome was not available for our sample
group; therefore, direct comparisons between cell cycle phase
distribution and the likelihood of recurrence could not be made.
An estimate of malignant potential was made, therefore, based on
histopathological features. The borderline tumours were graded on
a scale from 1þ to 3þ for cytological atypia and architectural
complexity by a specialist in gynaecological pathology (MJA).
Grading was based on the following features: 1þ, mild
architectural complexity with some multilayering/stratification of
cells with nuclei showing mild atypia; 2þ, moderate architectural
complexity with papillary projections, moderate mutilayering/
stratification of cells with nuclei showing moderate nuclear atypia;
and 3þ, marked architectural complexity with papillary projec-
tions and papillary branching and marked nuclear atypia. These
grades were then compared to the Mcm-2 LI, cyclin A LI and the
cyclin A LF for each group.
Statistical analysis
The LIs and LFs for the putative phase markers were compared
using the Kruskal–Wallis test. Pairwise comparisons from these
data were made by comparison of the median values (Mann–
Whitney U test). The Wilcoxon signed rank test with exact P-
values was used for paired comparisons between the percentages of
cells in each phase of the cell cycle determined by flow cytometry
and immunohistochemistry. Progressive differences for each
putative cell cycle phase marker across the groups of neoplasms
were compared using the Jonckheere–Terpstra (J-T) test, a
nonparametric statistical test to detect a shift in ordered
distributions when stratified by ordered categories.
RESULTS
Expression of MCM-2
In the normal ovary, Mcm-2 staining was seen in the epithelial
lining of small serous inclusion cysts. The number of cells
expressing Mcm-2 was low, with a median LI of 1.4% (Figure 1).
In the serous cystadenomas, the cyst wall was attenuated and the
epithelium formed a single layer of cuboidal or columnar cells. In
these lesions, the median Mcm-2 LI was 2.7%. The borderline
serous tumours showed a median Mcm-2 LI of 22.2%, with
expression seen both in the lining of attenuated cyst walls and in
papillary projections. The Mcm-2 LI was significantly in excess of
that seen in the serous cystadenomas (Po0.0001). The median
Mcm-2 LI for the serous cystadenocarcinomas was 80.4%.
Expression was diffuse within the serous cystadenocarcinomas,
although there was reduced expression in areas of necrosis. The
Mcm-2 LI in serous cystadenocarcinomas was significantly in
excess of that seen in borderline tumours (Po0.0001). There was a
significant increase in Mcm-2 expression on progression from
normal ovary through serous cystadenomas and borderline serous
tumours to serous cystadenocarcinomas (Po0.0001; J-T test)
(Figures 1 and 2, first column).
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Figure 1 MCM-2 LIs in normal ovarian epithelium and serous ovarian
neoplasms. Box and whisker plot comparing the Mcm-2 LI in normal ovary,
serous cystadenomas, borderline serous tumours and serous cystadeno-
carcinomas. Line¼median; box¼IQR; whisker¼2 IQR; cir-
cles¼extreme values.
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Cyclin D1 showed low-frequency nuclear expression in all
sample groups. Occasional cells additionally showed cytoplasmic
staining for cyclin D1, but these were not scored as cytoplasmic
staining probably represents background or aberrant antigen
retrieval. Scattered immunopositivity was seen in both borderline
tumours and serous cystadenocarcinomas but there were no
specific distribution patterns. Cyclin A showed a nuclear pattern
of staining similar to that seen for Mcm-2, although, as
expected, fewer cells were positive (Figure 2, second column).
The pattern of staining with cyclin B1 was predominantly
cytoplasmic (Figure 2, third column) with only occasional
cells showing nuclear staining. Phosphohistone H3 showed
both nuclear staining (presumed to be in prophase nuclei)
and staining of mitotic figures (Figure 2, fourth column). There
was a significant increase in the LIs for cyclin D1 (P¼0.002;
J-T test), cyclin A (Po0.0001; J-T test), cyclin B1 (Po0.0001; J-T
test) and phosphohistone H3 (Po0.0001; J-T test) with
progression from normal ovary through serous cystadenomas
and borderline serous tumours to serous cystadenocarcinomas
(Figure 3). Although the LI for cyclin D1 appears to fall
between borderline tumours and serous adenocarcinomas, this
is not statistically significant (P¼0.07) and the overall trend
is towards an increase in expression by the Jonckheere–
Terpstra test. Cyclin A and cyclin B1 LIs were elevated in
borderline tumours compared to cystadenomas (P¼0.003
and o0.0001, respectively) and in serous cystadenocarcinomas
compared to borderline tumours (P¼0.001 and o0.0001,
respectively).
Analysis of coexpression of cell cycle phase markers by
double-labelling confocal microscopy
There was coexpression of Mcm-2 in all epithelial cells from
cystadenocarcinomas and serous borderline tumours that ex-
pressed one of the cell cycle phase markers cyclins D1, A, B1 and
phosphohistone H3 (Figure 4a–c). We also performed double
staining to assess the degree of coexpression of adjacent cell cycle
phase markers in serous cystadenocarcinomas and borderline
serous tumours (Figure 4d–f). There was no coexpression of
phosphohistone H3 and cyclin D1 in any lesion examined,
consistent with the notion that cyclin D1 is detectable in vivo
during its phase of maximal expression in mid-to-late G1, but not
in early G1. There were occasional cells showing coexpression of
cyclin D1 with cyclin A (o5% of cyclin A-positive cells),
presumably identifying those cells around the G1/S transition.
There were very infrequent neoplastic cells showing coexpression
of cyclin A and cyclin B1 (5% of cyclin A-positive cells), suggesting
that cyclin A is detectable in vivo during its phase of maximal
expression in S, but not substantially in G2, similar to the staining
Mcm-2 Cyclin A Cyclin B1 Phosphohistone H3
Ovarian serous cystadenoma
Ovarian borderline serous tumour
Ovarian serous cystadenocarcinoma
Figure 2 Immunoperoxidase staining for cell cycle markers in serous ovarian neoplasms. The figure illustrates the patterns of expression of Mcm-2 (1st
column), cyclin A (2nd column), cyclin B1 (3rd column) and phosphohistone H3 (4th column) in serous cystadenomas (1st row), borderline serous tumours
(2nd row) and serous cystadenocarcinomas (3rd row). Whereas in cystadenomas there is only an occasional Mcm-2 positive epithelial cell, in borderline
tumours the epithelium shows widespread positivity for Mcm-2 and there is diffuse staining in the cystadenocarcinomas. Cyclin A and cyclin B1 LIs also
increase with progression towards a malignant phenotype. Note the predominantly cytoplasmic staining for cyclin B1, consistent with cells in G2, but with
occasional diffuse staining, consistent with entry into mitosis. Phosphohistone H3 detects only occasional nuclei in the cystadenomas and borderline tumours,
whereas cystadenocarcinomas show numerous positive nuclei, including mitotic figures.
Cell cycle analysis in ovarian neoplasms
IS Scott et al
1586
British Journal of Cancer (2004) 90(8), 1583–1590 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
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the cystadenocarcinomas, there was occasional coexpression of
cytoplasmic cyclin B1 with nuclear phosphohistone H3 (approx
1% of phosphohistone H3-positive cells), most likely representing
cells around the G2/M transition.
Phase distribution of cycling cells
The frequency of expression of each phase marker (LI) was
expressed as a percentage of the Mcm-2 positive cells to produce a
labelling fraction (LF) (Figure 5). The Mcm2-positive, phase
marker-negative cells were assumed to be in early G1 and these
cells were included with the cyclin D1-positive cells when
determining the G1 fraction. Application of the Jonckheere–
Terpstra test to these phase distribution results showed a decrease
in G1 fractions (P¼0.0008), and an increase in cyclin A (S phase;
P¼0.003) and cyclin B1 (G2 phase; Po0.0001) LFs on progressing
through the spectrum of serous neoplasia. There was no significant
change in the LF for phosphoshistone H3 (mitosis). These data are
consistent with increased S phase entry in cells of cystadenocarci-
nomas compared to cells of borderline tumours and cystadenomas.
Comparison of cell cycle phase distributions determined
by flow cytometry and immunohistochemistry
In total, 10 representative cases of serous cystadenocarcinoma were
examined by flow cytometry in addition to immunohistochemistry.
There was no significant difference in the S-phase fractions and G2/
M-phase fractions when estimated by the two methods (P¼0.17 and
0.06, respectively). In contrast, there was a difference in the G0/G1
fractions determined by the two methods (P¼0.017), with flow
cytometric analysis giving a lower estimate of the number of cells in
G0/G1 presumably due to nuclear fragmentation.
Borderline serous tumours: associations between grade
and cell cycle parameters
The 1þ borderline tumours had a lower Mcm-2 LI than either the
2þ or 3þ tumours (P¼0.04), but there was no significant
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Figure 3 Cell cycle phase marker LIs in normal ovarian epithelium and
serous ovarian neoplasms. Comparison of cell cycle phase marker
expression (LIs) in normal ovary (normal ovary), serous cystadenomas
(serous adenoma), serous borderline tumours (borderline tumours) and
serous cystadenocarcinomas (serous adenoCA). Line¼median;
box¼IQR; whisker¼2 IQR.
Mcm-2 and cyclin A  Mcm-2 and cyclin B1 Mcm-2 and phospho-H3
Cyclin A and cyclin B1 Cyclin B1and phospho-H3 Phospho-H3 and cyclin D1
ABC
DEF
Figure 4 Double labelling confocal microscopy in serous cystadenocarcinomas. (A–C) Staining for Mcm-2 and phase-specific markers. (A) Mcm-2
(green) and cyclin A (red). The majority of cells express Mcm-2 (green). Occasional cells are yellow, representing cells positive for cyclin A in which Mcm-2 is
coexpressed. No cells are positive for cyclin A in the absence of Mcm-2. (B) Mcm-2 (green) and cyclin B1 (red). Occasional Mcm-2 positive cells coexpress
cyclin B1, which produces a red cytoplasmic halo in cells in G2 (arrow). (C) Mcm-2 (green) and phosphohistone H3 (red). Phospho-H3 stains the mitotic
figures, in cells that have a green cytosol because of exclusion of Mcm-2 from condensed chromatin. (D–F) Staining for markers of adjacent cell cycle
phases. (D) Cyclin A (green) and cyclin B1 (red) are coexpressed in a maximum of 5% of cyclin A-positive cells. (E) Cyclin B1 (green) and phosphohistone
H3 (red) are coexpressed in less than 2% of phosphohistone H3-positive cells, unless the cyclin B1 staining is nuclear, indicating entry into prophaseo f
mitosis (arrow). (F) There is no coexpression of phosphohistone H3 (red) and cyclin D1 (green).
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ydifference between the 2þ and 3þ tumours. There was a stepwise
increase in both cyclin A LI and the S-phase fraction (cyclin A LF)
as the histological features increased from 1þ through 2þ to 3þ.
This suggests that either the cyclin A LI or the S-phase fraction has
the potential to aid discrimination between different grades within
this group of serous borderline tumours (Figure 6).
DISCUSSION
Ovarian serous tumours of borderline malignant potential will
normally behave in an entirely benign manner; however, 15–30%
of these tumours have the potential for aggressive behaviour and
may exhibit malignant change. This hypothesis is based on ovarian
tumours showing a continuum of progression from serous
borderline tumours to serous cystadenocarcinomas. This concept
is widely accepted and is based largely on both histopathological
observation of foci of microinvasion within borderline tumours
and cytogenetic evidence showing similar chromosomal alterations
in both types of ovarian neoplasm, and also in serous adenomas,
particularly those involving chromosome 6 (Tibiletti et al, 2001,
2003). There is evidence, however, to suggest that each of these
tumour entities may arise de novo and these studies are based
largely on the patterns of mutations in TP53 and K-RAS, each of
which can show considerable heterogeneity (Teneriello et al, 1993;
Herbst, 1994; Miki et al, 1994; Ortiz et al, 2001). A further model
suggests a dual pathway in which some, often the more aggressive
tumours, arise de novo and others, the majority, arise by stepwise
progression from borderline tumours (Singer et al, 2002, 2003).
Our data, showing a consistent progression of markers of cell cycle
entry and cell cycle phase, would favour the stepwise progression
model in this small subset of serous neoplasms.
Currently, a diagnosis of borderline tumour is made where there
are histologically atypical features without evidence of destructive
stromal invasion. No specific marker has yet been identified,
however, that is able to separate reliably this diagnostic entity into
benign and malignant prognostic groups. An accurate indication
of cell cycle state and phase distribution may be of value in this
regard.
An immunohistochemical method to estimate cell cycle phase
distribution in situ using tissue sections has considerable
advantages in the routine diagnostic setting compared to existing
methods of cell cycle analysis such as flow cytometry (Scott et al,
2003) and overall comparisons suggest that our immunohisto-
chemical method is able to produce cell cycle analyses comparable
to those obtained by flow cytometry.
A potential criticism of an immunohistochemical method, such
as the one described here, is that the counts may not be
reproducible as only a small proportion of the total cells are
assessed. In our study the cell cycle counting was performed by
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Figure 5 Cell cycle phase distribution in cycling cells. Stacked bar graph
illustrating the phase distribution of cells in each sample group determined
as fractions of the number of cells in cycle (as defined by the expression of
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and M from the phosphohistone H3 LF. G1 is the difference between the
Mcm-2 LI and the sum of each of the above LFs. The S and G2 fractions
increase across the groups (P¼0.003 and o0.0001, respectively), and
there is a corresponding decrease in the G1 fraction (P¼0.0008).
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Figure 6 Cell cycle parameters in borderline serous tumours of different
grades. Values obtained for Mcm-2 LI (top), cyclin A LI (middle) and the S-
phase fraction (cyclin A LF, bottom) in borderline serous tumours scoring
1þ (left column), 2þ (middle column) and 3þ (right column) for both
architectural and cytological atypia.
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that we observed is comparable with values from many other
methods and offers the advantage that areas of tumour hetero-
geneity can be identified and morphologically different areas can
be assessed.
We have observed in a parallel study that Mcm-2 was expressed
in more cells in normal and neoplastic ovary than the traditional
marker Ki67 (data not shown). Moreover, antibodies against Ki67
fail to stain all the cells labelling with phosphohistone H3 and
occasional cells labelling with cyclin D1 (Chatrath et al, 2003). In
contrast, Mcm-2 identifies every cell expressing a marker of cell
cycle phase, demonstrating its value as a marker of cell cycle entry
(Scott et al, 2003). The Mcm-2 positive, cell cycle phase marker
negative cells were assumed to be in early G1 but, as there is no
reliable marker of this phase of the cell cycle, this hypothesis
cannot be substantiated at the current time. Nevertheless, our data
suggest that Mcm-2 may offer advantages over Ki67 as a marker of
the cell cycle ‘state’ of tissues.
Confocal microscopy suggested that cyclins D1, A and B1 and
phosphohistone H3 do not show any significant coexpression in
ovarian neoplasms, unlike data from some tumour cell lines (Pines
and Hunter, 1992). The relative S-phase specificity of immunode-
tectable cyclin A in ovarian tumours was demonstrated by the
minimal coexpression of cyclin A with cyclins D1 and B1, used as
markers of mid-to-late G1 and G2 phases, respectively, and the
good correlation with flow cytometric estimates of S-phase cells.
Similar observations were also made in our earlier study of
colorectal carcinoma (Scott et al, 2003), in which cyclin A
expression was also not detected in any cell not seen to be actively
replicating DNA using our in situ replication assay (Mills et al,
2000). In order for in situ DNA replication to be effective,
the tissue must be rapidly removed and snap-frozen in liquid
nitrogen to preserve the DNA synthetic machinery within the cells.
Such a study could not be repeated for the ovarian neoplasms
because of the prolonged ischaemic time involved in gynaecolo-
gical surgery. Taken together, our data suggest that cyclin A
expression can be used as a surrogate immunohistochemical
marker of S phase and that the cyclin A/Mcm2 ratio in ovarian
neoplasms can be used to estimate the fraction of cycling cells that
are in the S phase.
We observed an increase in the LIs of Mcm-2, cyclins D1, A and
B1 and phosphohistone H3 in ovarian serous cystadenocarcinomas
compared to borderline serous tumours, serous cystadenomas and
normal ovary. The findings we describe for Mcm-2 are similar to
those obtained in previous studies using Ki67 (Garzetti et al, 1995;
Blegen et al, 2000). Indeed, it has been shown previously that
tumour cell proliferation, as assessed by the Ki67 LI, was
significantly higher in cases of serous ovarian cystadenocarcinoma
that recurred or progressed than in those that did not (Garzetti
et al, 1995). In the present study, we did not observe the very high
frequency of expression of MCMs that was seen in serous
inclusions in four cases of normal ovary in a previous study
(Freeman et al, 1999).
Increases in the cyclin D1 LIs were observed in the serous
cystadenocarcinomas. Dhar et al (1999) found 13.5% of serous
ovarian cystadenocarcinoma cells to be cyclin D1 positive
compared with 1.58% in our study. This disparity is most
likely to be due to differences in antigen retrieval. We have found
anti-cyclin D1 antibodies difficult to work with. Variations in the
time and method of antigen retrieval can alter the binding
characteristics and cellular localisation of this antibody by a
considerable margin (720%), while still producing minimal
background staining. The apparent reduction in cyclin D1
expression on progression from borderline tumours to serous
cystadenocarcinomas may reflect dysregulation of the G1/S
checkpoint in the higher grade lesions as cyclin D1 is known to
accumulate in the presence of an intact G1/S checkpoint (Berardi
et al, 2003).
Determination of cyclin A LFs may be of greater value in
predicting outcome and/or the likely response to chemotherapy,
by indicating the fraction of cycling tumour cells (rather than the
total number of tumour cells) that are in S phase. Indeed, we have
shown previously in colorectal carcinomas that cyclin A LFs give a
greater range of values for S-phase cells than do cyclin A LIs or
flow cytometry (Scott et al, 2003). When investigating whether cell
cycle parameters varied within the group of borderline serous
neoplasms, we observed an increase in Mcm-2 LI, cyclin A LI and
the cyclin A LF (S-phase fraction) with increasing histopatholo-
gical grade. It may be that these parameters would be of clinical
value in predicting outcome, as has been shown in other types of
malignancy, such as breast carcinoma (Gonzales et al, 2003).
Testing this hypothesis would require a much larger series of cases
for which there was adequate outcome data, taking into account
histological grade and stage, treatment received and with
corrections for lead and lag-time bias.
In conclusion, the immunohistochemical method for cell cycle
assessment that we describe offers numerous practical benefits, in
that it is reproducible, can be standardised in any diagnostic
histopathology laboratory and the analysis can be confined to the
neoplastic component. Unlike flow cytometric assessment of
homogenised samples, the method enables separate examination
of multiple sites within a tumour, allowing an evaluation of the
considerable heterogeneity that can exist. We have demonstrated
that in ovarian serous neoplasms, expression of all markers of cell
cycle state and phase increased on progression from benign
through borderline to malignant tumours. Estimation of para-
meters such as Mcm-2 LI or cyclin A LF (S-phase fraction) in
tissue sections may prove to be a highly convenient means of
predicting clinical outcome in borderline serous tumours and
serous cystadenocarcinomas.
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